quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·37d
PRRelease
Tempus AI Inc. logo

Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries

TEM· Tempus AI Inc.
Technology
Original source

Companies

  • TEM
    Tempus AI Inc.
    Technology

Recent analyst ratings

  • Apr 13UpdateJefferies$35.00
  • Apr 13UpdateTD Cowen$65.00
  • Feb 19UpdateMizuho$100.00
  • Feb 17UpdateRobert W. Baird$59.00
  • Dec 2UpdateMorgan Stanley$85.00
  • Oct 21UpdateTD Cowen$88.00

Related

  • PR19h
    Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights
  • PR22h
    Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine
  • PR2d
    Tempus to Report First Quarter 2026 Financial Results on May 5
  • PR8d
    Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring
  • PR9d
    Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026
  • ANALYST10d
    Jefferies initiated coverage on Tempus AI with a new price target
  • ANALYST10d
    Tempus AI upgraded by TD Cowen with a new price target
  • PR10d
    Tempus Launches Automated "Active Follow-Up" Service to Support Guideline-Concordant Care
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022